Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 0001

DEPTOR as a target for the treatment of chronic inflammation and angiogenesis-dependent diseases

Inventors: David Briscoe

Invention Types: Therapeutics

Research Areas: Cardiovascular/Cardiology, Immunology

Keywords: Drug Discovery

For More Information Contact:  Caron, Connie

 

Invention Description:

Researchers in Dr. Briscoe’s laboratory have demonstrated that DEPTOR, DEP domain containing mTOR interacting protein, is expressed in microvascular endothelial cells (EC) and functions as an upstream regulator of EC activation responses and EC-dependent proinflammatory responses.


Using a transgenic mouse model in which intracellular DEPTOR expression can be manipulated and sustained, Dr. Briscoe’s lab have now shown that DEPTOR functions in a similar manner in T-cells. By forcing expression of DEPTOR, they observed that T-cells remained quiescent typical effector function was not achieved. To modulate DEPTOR, they discovered that a small molecule inhibitor of a Cullin ligase that controls DEPTOR degradation can also target DEPTOR in T cells and this compound allowed DEPTOR to remain overexpressed in both EC and T cells. This suggests that families of such molecules may serve as a potent anti-inflammatory agent that sustains DEPTOR levels and its regulatory effects on downstream signaling pathways.

Applications:

• Novel treatment pathway for chronic inflammatory or angiogenesis-dependent disorders

Business Opportunity:

• Sponsored research opportunity

Key Publications: Bruneau et al., 2013. DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. Blood 122(10): 1833-1842
On line at: http://www.atcmeetingabstracts.com/abstract/deptor-is-expressed-in-cd4-t-cells-and-modulates-effector-responses-and-allograft-rejection/

IPStatus: Not applicable